Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Once reconstituted, refrigerate at 2-8C
So, talk to your doctor if you take any of these
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
This makes it particularly effective for injuries involving connective tissues that are notoriously slow to heal on their own
The compound was first reported in Al-Obeidi, Castrucci, Hadley, and Hruby, J Med Chem 32 (12):255561 (1989) (PMID 2555512), building on the earlier open-chain superpotent precursor [Nle, D-Phe]--MSH reported by Sawyer, Sanfilippo, Hruby, Engel, Heward, Burnett, and Hadley in PNAS 77 (10):57548 (1980) (PMID 6777774)
US$ 27.09
US$ 29.02
US$ 22.04
